Forum Financial Management LP Sells 17,417 Shares of Abbott Laboratories $ABT

Forum Financial Management LP decreased its position in Abbott Laboratories (NYSE:ABT) by 27.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 46,820 shares of the healthcare product maker’s stock after selling 17,417 shares during the quarter. Forum Financial Management LP’s holdings in Abbott Laboratories were worth $4,807,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of ABT. Brighton Jones LLC raised its position in Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares during the last quarter. Sivia Capital Partners LLC grew its position in shares of Abbott Laboratories by 3.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after buying an additional 162 shares during the last quarter. United Bank increased its stake in shares of Abbott Laboratories by 7.4% during the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after buying an additional 2,001 shares during the period. Main Street Financial Solutions LLC raised its holdings in shares of Abbott Laboratories by 13.6% during the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock valued at $1,618,000 after acquiring an additional 1,428 shares in the last quarter. Finally, Canada Pension Plan Investment Board lifted its stake in Abbott Laboratories by 25.6% in the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock worth $195,267,000 after acquiring an additional 292,547 shares during the period. 75.18% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on ABT shares. Evercore reduced their price objective on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Mizuho dropped their target price on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a research report on Friday, April 17th. Citigroup reduced their price target on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Weiss Ratings lowered shares of Abbott Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, June 16th. Finally, Raymond James Financial reduced their target price on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $118.30.

Abbott Laboratories Stock Down 1.4%

NYSE:ABT opened at $92.78 on Tuesday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The firm’s 50-day moving average price is $89.03 and its 200-day moving average price is $105.07. The company has a market capitalization of $161.60 billion, a PE ratio of 25.99, a P/E/G ratio of 1.62 and a beta of 0.63. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping the consensus estimate of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. Abbott Laboratories’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities analysts predict that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be paid a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.7%. Abbott Laboratories’s dividend payout ratio is presently 70.59%.

Insider Activity at Abbott Laboratories

In related news, CFO Philip P. Boudreau acquired 2,200 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, April 23rd. The stock was bought at an average price of $91.50 per share, with a total value of $201,300.00. Following the transaction, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction on Monday, April 27th. The shares were bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director directly owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. The trade was a 0.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 0.46% of the company’s stock.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The U.S. Justice Department reportedly closed its criminal probe into Abbott’s baby formula operations and chose not to pursue criminal charges, which removes a major overhang and reduces the risk of a damaging legal outcome. US DOJ closes criminal probe into Abbott over baby formula plant, WSJ reports
• Positive Sentiment: Abbott’s Medical Devices business is being positioned for another growth phase, with new diabetes, heart rhythm, and electrophysiology products cited as potential drivers ahead of the company’s next earnings update. How Abbott’s Largest Segment Is Preparing for the Next Growth Phase
• Neutral Sentiment: Healthcare stocks were modestly higher late Monday afternoon, but Abbott still lagged peers and underperformed the sector, suggesting the stock’s move was more idiosyncratic than industry-wide. Sector Update: Healthcare Stocks Higher Late Afternoon
• Neutral Sentiment: Market commentary also highlighted Abbott’s baby formula probe being dropped by the DOJ, reinforcing the legal relief narrative, though investors may still wait for clarity on any civil penalties or follow-on costs. Update: Market Chatter: Abbott Laboratories Baby Formula Probe Dropped by DOJ After Years-Long Investigation Into Contamination Risks
• Negative Sentiment: Despite the DOJ news, Abbott’s shares traded lower and underperformed competitors, indicating that investors may be taking profits or focusing on broader concerns around valuation, growth, or lingering legal uncertainty. Abbott Laboratories stock underperforms Monday when compared to competitors

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.